Compare VVV & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVV | ACAD |
|---|---|---|
| Founded | 1866 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.8B |
| IPO Year | 2016 | 2000 |
| Metric | VVV | ACAD |
|---|---|---|
| Price | $33.06 | $21.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 22 |
| Target Price | ★ $40.00 | $30.55 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.86 | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | ★ $2,285,000,000.00 | $726,437,000.00 |
| Revenue This Year | $20.80 | $18.80 |
| Revenue Next Year | $10.50 | $11.70 |
| P/E Ratio | ★ N/A | $9.80 |
| Revenue Growth | 9.64 | ★ 40.45 |
| 52 Week Low | $28.50 | $14.45 |
| 52 Week High | $41.33 | $28.35 |
| Indicator | VVV | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 49.42 |
| Support Level | $31.76 | $21.51 |
| Resistance Level | $33.45 | $22.97 |
| Average True Range (ATR) | 1.08 | 0.61 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 42.27 | 54.43 |
Valvoline Inc provides automotive preventive maintenance through retail stores across the U.S. and Canada, offering approximately 15-minute stay-in-your-car oil changes, battery, bulb, and wiper replacements, tire rotations, and other manufacturer-recommended maintenance. Its full-service oil changes include Valvoline oil, a new oil filter, chassis lubrication, and an 18-point maintenance check. The Company provides differential fluid, fuel system cleaning, headlight and taillight replacement, radiator service, transmission service, air conditioning, and air filter replacement. It operates and franchises approximately 2,200 Valvoline Instant Oil Change and Valvoline Great Canadian Oil Change retail locations. The majority of revenue is generated from the United States of America.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.